Q-omics provides the consensus-scored CXADRP2 profile across patient tissues and cancer cell-line models. CXADRP2 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, CXADRP2 is differentially expressed in 5, with the highest sampling consensus in UCEC. Additionally, CXADRP2 RNA expression shows 5,739 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, UCEC, and STAD as cancer lineages where CXADRP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CXADRP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CXADRP2 survival associations across molecular data types. CXADRP2 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CXADRP2 RNA expression–survival associations across cancer types. High CXADRP2 expression shows unfavorable associations in KICH, UCS, OV, ESCA and COAD, but favorable associations in PAAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for CXADRP2 RNA expression.
This table summarizes CXADRP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CXADRP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CXADRP2 shows lower tumor expression in STAD and higher tumor expression in UCEC, BRCA, PRAD and LUAD. The UCEC box plot shows higher CXADRP2 RNA expression in tumor versus normal tissue (log2 FC = +0.034, t-test p = .023).
This table shows molecular features associated with CXADRP2 in patient tissues and cancer cell lines. In patient samples, CXADRP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
